INmune Bio Inc INMB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $2.08
- Day Range
- $2.04–2.20
- 52-Week Range
- $1.09–2.58
- Bid/Ask
- $2.15 / $2.16
- Shares Outstanding
- 27.75M
- Market Cap
- $60.23M
- Volume/Avg
- 462,033 / 778,326
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 21
- Website
- https://www.inmunebio.com
Valuation
|
Metric
|
INMB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.95 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
INMB
|
|---|---|
Quick Ratio | 3.94 |
Current Ratio | 4.04 |
Interest Coverage | — |
Quick Ratio
INMB
Profitability
|
Metric
|
INMB
|
|---|---|
Return on Assets (Normalized) | −29.67% |
Return on Equity (Normalized) | −39.32% |
Return on Invested Capital (Normalized) | −37.57% |
Return on Assets
INMB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|sj?HP! | LOCK|sT##R | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^wc$x&y | LOCK|&D$% | $83B | |||
| argenx SE ADR
ARGX
| LOCK|#G^?mj | LOCK|Y&& | $53B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|d$Nkzly | LOCK|V!lN | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Q^?$gx | LOCK|SJ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|s<#!fhx | LOCK|c<&c! | $31B | |||
| Moderna Inc
MRNA
| LOCK|>gz>qB@ | LOCK|dD | $25B | |||
| Incyte Corp
INCY
| LOCK|fm?>@L! | LOCK|^Y | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|nK%Dm#k | LOCK|WgM | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|?VY?&w | LOCK|Z%M | $16B |
United States